Recovery of Endogenous β-Cell Function in Nonhuman Primates After Chemical Diabetes Induction and Islet Transplantation by Bottino, Rita et al.
Recovery of Endogenous -Cell Function in Nonhuman
Primates After Chemical Diabetes Induction and Islet
Transplantation
Rita Bottino,
1 Angela Criscimanna,
1,2 Anna Casu,
1 Jing He,
1 Dirk J. Van der Windt,
1
William A. Rudert,
1 Carla Giordano,
2 and Massimo Trucco
1
OBJECTIVE—To describe the ability of nonhuman primate
endocrine pancreata to reestablish endogenous insulin produc-
tion after chemical -cell destruction.
RESEARCH DESIGN AND METHODS—Eleven monkeys
(Macaca fascicularis) were rendered diabetic with streptozoto-
cin. Eight diabetic monkeys received intraportal porcine islet
transplantation.
RESULTS—Two monkeys transplanted after 75 days of type 1
diabetes showed recovery of endogenous C-peptide production a
few weeks after transplantation, concomitant with graft failure.
Histological analysis of the pancreas of these monkeys showed
insulin-positive cells, single or in small aggregates, scattered in
the pancreas and adjacent to ducts. Interestingly, numerous
CK19
 cells costained with proinsulin and PDX-1 antibodies.
Furthermore, the peculiar double phenotype glucagon-positive/
GLUT2
 was observed. In these monkeys as well as in all others,
the original islets showed no insulin staining.
CONCLUSIONS—Our data provide evidence that, in nonhuman
primates, the pancreas can reestablish endogenous insulin pro-
duction after chemical -cell destruction. This seems to be a
nongeneralizable event with only 2 out of 11 monkeys recovering
-cell function. In these two monkeys, younger age and islet graft
behavior might have played a role in triggering endogenous -cell
recovery. Diabetes 58:442–447, 2009
U
ntil a few years ago, lesions of the endocrine
pancreas, as occur in type 1 diabetes, were
thought to be permanent and irreversible, since
diabetic patients require hormone replacement
therapy for life (1). Despite the clinical evolution of the
disease, it is still unknown whether the islet -cells possess,
at least in part, the ability to heal from an injury (2).
In mouse models, evidence has accrued that adult
animals retain the ability to expand their -cell mass after
stimulation with a variety of triggers (3–8). It remains
largely uncertain, however, through which molecular and
cellular mechanisms the reparative process works (2).
In humans, the ability of the postnatal pancreas to
expand the -cell mass after injury is still debated (9,10).
Spontaneous recovery of -cell function has been reported
in only few patients previously diagnosed with type 1
diabetes (11).
Although nonhuman primates do not develop autoim-
mune diabetes, a permanent diabetes status can be in-
duced by total pancreatectomy or by chemical destruction
of the -cells with streptozotocin (STZ) (12,13).
In this study, a group of 11 monkeys were rendered
diabetic by high STZ doses. Eight of them received
intraportal pig islet transplantations under an immuno-
suppressive regimen based on anti-CD154 antibody and
mycophenolate mofetil (14).
In two recipients where pig islet grafts functioned for a
few weeks and eventually failed, we observed increasing
endogenous C-peptide production paralleled by metabolic
improvement. We reviewed all metabolic data, did exten-
sive histological analysis, and here report evidence of
recovery of endogenous insulin production in these two
monkeys.
RESEARCH DESIGN AND METHODS
A total of 15 male Cynomolgus monkeys (Macaca fascicularis) (Three Spring
Scientiﬁc, Perkasie, PA), 2–4 years old and 2.6–4.7 kg (median 3.6 kg), were
included in the study.
Four wild-type retired breeder pigs (Wally Whippo, Enon Valley, PA) and
three GT-DKO pigs (-1,3-galactosyltransferase KO pigs; Revivicor, Blacks-
burg, VA) of similar weight were used as sources of pancreata for islet
isolation. One wild-type pig was used for two transplants. All animal care
procedures were in accordance with the institutional Principles of Laboratory
Animal Care.
Induction of diabetes. Diabetes was induced in 11 monkeys with 125–150
mg/kg i.v. of Zanosar STZ (Sicor Pharmaceuticals, Irvine, CA) in a single dose
(12).
Islet preparation and transplantation. After pancreatectomy in the anes-
thetized donor pig, islet isolation was carried out according to a modiﬁcation
of the method described for human islets, optimized for pigs (15). Intraportal
injection of islets (an average of 60,000 islet equivalents/kg body wt with a
range of 40,000–100,000 islet equivalents/kg) resuspended in plain CMRL-1066
with addition of heparin (70–140 units/kg; Baxter, Deerﬁeld, IL) or dextran
sulfate (molecular weight 5,000 d; 4 mg/kg; Fluka, Buchs, Switzerland) was
carried out under general anesthesia of recipients.
Immunosuppressive management in transplanted monkeys. After induc-
tion with anti-thymocyte globulin, immunosuppression was maintained with
humanized anti-CD154 monoclonal antibody (ABI 793, generously provided by
Novartis Pharma, Basel, Switzerland) and mycophenolate mofetil (Roche,
Nutley, NJ) (14).
Anticoagulation/antiaggregation/anti-inﬂammatory treatment was achieved
with heparin or dextran sulfate, prostacyclin (GlaxoSmithKline, Research Trian-
gle Park, NC), and aspirin (14).
Diabetes and graft/endogenous -cell function monitoring. Blood glu-
cose (mmol/l) was measured in whole blood with Free Style (Lifescan).
Primate C-peptide (nmol/l) levels were measured by radioimmunoassay
(Linco Research, St. Charles, MO). Conﬁrmatory post-STZ C-peptide levels
were measured using a chemiluminescent-based technology (Bayer Centaur,
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442 DIABETES, VOL. 58, FEBRUARY 2009Tarrytown, NY). Porcine C-peptide (nmol/l) was detected by radioimmunoas-
say (Linco Research). Intravenous glucose tolerance tests were carried out
before and after transplantation, as described (14).
Fixation and immunostaining of specimens. Monkeys were killed at the
time of rejection or when the vascular lines stopped working. Specimens of
the pancreatic tissue were obtained, ﬁxed, and analyzed as described in
Supplemental Methods (found in an online appendix at http://dx.doi.org/10.
2337/db08-1127). Morphometric analysis was conducted as per Bouwens and
Pipeleers (16).
RESULTS
Recovery of endogenous C-peptide. All monkeys
treated with STZ became hyperglycemic (blood glucose
15 mmol/l) within 48 h and required exogenous insulin.
Fasting C-peptide was under detection levels (0.16
nmol/l) in all treated animals using a chemiluminescent
method. Using commercially available ultra-sensitive ra-
dioimmunoassay kits, the monkeys showed an overall
reduction in C-peptide of at least 75% compared with the
pre-STZ values (Fig. 1A). Lack of C-peptide increased 5
min after glucose infusion during an intravenous glucose
tolerance test after STZ treatment characterized all treated
monkeys. Diabetic monkeys that did not undergo trans-
plantation (n  3) and islet recipients with early graft loss
(n  6) (characterized by undetectable or low porcine
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FIG. 1. A: Endogenous C-peptide levels before and after STZ treatment. Closed triangles indicate the values of C-peptide in the two monkeys that
recovered autologous insulin production. B: Relative increase of endogenous C-peptide over basal post-STZ values. Solid lines indicate
STZ-diabetic monkeys that were not transplanted (n  3) as well as STZ-diabetic recipients that experienced early graft loss (n  6). Dotted lines
represent the monkeys with recovered -cell function (n  2). C–F: Metabolic proﬁle of the monkeys with recovered endogenous C-peptide
(M4804 and M5204). C and E: Graft (porcine) and endogenous (primate) C-peptide levels. D and F: Blood glucose and exogenous insulin
administration.
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autologous C-peptide over the post-STZ basal levels (Fig.
1B). Exogenous insulin requirements after graft failure or
in nontransplanted monkeys remained unchanged over
time (data not shown). The pancreatic islets of monkeys
with STZ-induced diabetes showed complete absence of
insulin immunostaining (Supplemental Fig. 1). Monkeys
M4804 and M5204, with C-peptide levels below detection
using both detection methods for 2 months after STZ
treatment, showed substantial recovery of basal endoge-
nous C-peptide after a period of 3 weeks with islet graft
function (Fig. 1B). Interestingly, the curves representing
endogenous versus porcine C-peptide followed opposite
trends (Fig. 1C and E). Glycemia did not worsen after graft
failure, exogenous insulin requirement was lower than
before transplantation, possibly because of the autologous
insulin production (Fig. 1D and F), and body weight
increased at the pace of healthy monkeys. Several weeks
after transplantation, endogenous C-peptide levels were
not only detectable but showed a low but measurable
response to glucose stimulation (Supplemental Fig. 2).
After islet graft failure in all other recipients, glycemia and
insulin requirements returned to pretransplantation levels
or worsened (data not shown), while endogenous C-
peptide did not increase. In monkeys with long-term graft
function (3 and 12 months), recovery of endogenous
insulin production was not observed (R.B., A.Cr., A.Ca.,
J.H., D.J.V.d.W., W.A.R., C.G., M.T., unpublished data).
Histological ﬁndings. The pancreata of all the monkeys
were analyzed for the presence of proinsulin-positive cells.
The two monkeys that reestablished endogenous C-pep-
tide production showed several proinsulin-positive cells
grouped in small aggregates, or single cells scattered
throughout the pancreas but distant from aggregates of
glucagon-positive cells (Fig. 2). We quantiﬁed the number
of proinsulin-positive cell clusters with area 30 m
2 (i.e.,
cell clusters not included in the islets of Langerhans
existing before STZ treatment nor in the ducts). Proinsu-
lin-positive cell clusters covered 0.23 and 0.18% of the
whole section area in M5204 and M4804, respectively.
These values were higher than in STZ-diabetic controls
(0.05 	 0.0004%; n  4 different monkey pancreata) but
lower than nondiabetic monkeys (0.30 	 0.01%; n  3
monkey pancreata). Proinsulin-positive cells were co-
stained with PDX-1 (Fig. 3N and Supplemental Fig. 3).
Interestingly, anti-CK19 antibody, used to identify the
ductal/epithelial cells, was costained with proinsulin-pos-
itive cells in these monkeys (Fig. 3A–H). The pancreata of
these monkeys showed stronger CK19 expression in com-
parison to nondiabetic and STZ-diabetic, transplanted, and
nontransplanted controls (Supplemental Fig. 4).
Additionally, the monkeys with recovered -cell func-
tion presented double PDX-1
/CK19
 staining (Fig. 3K–
M). PDX-1
 cells were also found in STZ-diabetic control
monkeys, but they did not costain with CK19 (Fig. 3J) nor
with proinsulin (data not shown). The atypical GLUT2/
glucagon phenotype was found in islets devoid of insulin-
producing cells in M4804 and M5204 (Fig. 4A and lower
panel), whereas it was not observed in STZ-diabetic (Fig.
4C) nor in nondiabetic control monkeys (Fig. 4B).
Anti-Ki67 antibody was used as a nuclear marker of
active cell proliferation. Anti-Ki67 stained CK19
 cells and
ﬁbroblasts but not proinsulin-positive cells (data not
shown).
FIG. 2. Proinsulin-positive cells in the monkeys with recovered endogenous -cell function. A–C: Proinsulin-positive cells are organized in small
aggregates or scattered as single cells in the pancreas, not associated with glucagon-positive cells. White arrows: proinsulin-positive cells. Yellow
arrows: glucagon-positive cells, presumably islets with damaged -cells. D–F: Higher magniﬁcation. Pictures are representative of both monkeys
with recovered endogenous -cell function. (Please see http://dx.doi.org/10.2337/db08-1127 for a high-quality digital representation of this
ﬁgure.)
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In rodents, regenerative properties of -cells have been
unveiled (6,7). In humans, there is no clear similar indica-
tion. The autoimmune process that causes type 1 diabetes
in the ﬁrst place might also be responsible for halting
potential attempts at restoring insulin production (2).
Nonetheless, it is unclear, even in the absence of the
immune attack, if the pancreatic -cell function can re-
cover efﬁciently (17). Anecdotic reports describing return
to a normoglycemic status in patients diagnosed and
treated for type 1 diabetes seem to prove that islet
function can be reestablished in humans, concurrent with
the disappearance of autoimmunity (11). In nonhuman
primates used for preclinical investigation of type 1 diabe-
tes treatments, hyperglycemia can be induced by adminis-
tration of STZ. Once C-peptide is signiﬁcantly reduced and
exogenous insulin administration begins, in contrast to
that observed in rodents, spontaneous normoglycemia is
believed to be unrecoverable (18).
However, in our hands, two nonhuman primates ren-
dered diabetic with STZ and with virtually no endogenous
residual -cell function for 2 months regained endogenous
insulin production concomitant with pig islet graft failure.
At the time they were killed, endogenous C-peptide levels
were 10 times higher than after STZ treatment with
associated lower insulin requirements, despite C-peptide
being below the normal range of a nondiabetic cynomol-
gous monkey (14).
The posttransplantation clinical course of these two
monkeys was characterized by glycemic levels persistently
higher than in the normal physiologic range, despite graft
insulin production, but well below the range recorded in
nontransplanted diabetic monkeys. It is a common notion
that chronically elevated blood glucose levels have a
negative impact on -cell function, but it is also known
that glucose infusion and mild hyperglycemia may stimu-
late growth of the -cell mass. It is unclear whether a
threshold for beneﬁcial/toxic effect indeed exists in mon-
keys and if this effect may have played a role in triggering
recovery of insulin production in our monkeys. We ob-
served that in the six monkeys with short graft function
and consequent severe hyperglycemia and those that
returned to stable normoglycemia after transplantation
(R.B., A.Cr., A.Ca., J.H., D.J.V.d.W., W.A.R., C.G., M.T.,
unpublished data; 19), no recovery of the endogenous
function occurred.
Histological examination of the pancreas of these
two monkeys showed scattered proinsulin-positive cells,
mostly organized as single cells or in small clusters, not
associated with glucagon-positive cells, but often to ducts,
similar to the ones just recently described (8,20). The
frequency of small proinsulin-positive cell aggregates was
higher in the monkeys with recovered -cell function than
in diabetic controls but lower than in nondiabetic mon-
keys. While on one hand we may hypothesize that new
cells formed, data do not allow to rule out that proinsulin-
positive cells result from a degranulation-regranulation
process, as described by Sherry in the autoimmune NOD
mouse model (21). However, if regranulation were the
mechanism of recovery of the -cells, proinsulin-positive
FIG. 3. A–H: Presence of double phenotype CK19/proinsulin in monkeys with recovered endogenous -cell function. A–D: Monkeys with recovered
endogenous -cell function show co-expression of CK19 with proinsulin (yellow). E–H: Detail of a pancreatic duct. I–N: Double PDX-1
/CK19

in the pancreas of monkeys with recovered function (K with detail in L, and M). CK19 and PDX-1 do not co-stain in nondiabetic healthy monkeys
(I); PDX-1
 cells are found scattered throughout the pancreas of STZ-diabetic monkeys, but do not co-localize with CK19 (J); M and N:
consecutive pancreatic sections in M5204 (monkey with recovered -cell function) showing CK19
/PDX-1
 (M) and CK19
/proinsulin-positive
(N) cells, respectively. Arrows show PDX-1
 cells in J; double positive PDX-1
/CK19
 in K, L, and M; and PDX-1
/proinsulin-positive in N. (Please
see http://dx.doi.org/10.2337/db08-1127 for a high-quality digital representation of this ﬁgure.)
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glucagon-positive cell aggregates) should have been seen.
Interesting features in the pancreas of these monkeys
were the presence of proinsulin-positive cells expressing
CK19 within and outside the ducts as well as CK19
/PDX-
1–positive/proinsulin-positive cells, suggesting that -cells
may have formed ex novo from duct progenitors, recapit-
ulating pancreatic organogenesis and neogenesis. In agree-
ment with this observation seems to be the molecular
analysis of factors physiologically involved in organogen-
esis, although the modest numbers of monkey tissue for
this study limits the soundness of the conclusion (Supple-
mental Fig. 5).
An additional characteristic of the pancreas of these
monkeys was the presence of
. glucagon-positive/GLUT2

cells. A lack of evidence for glucagon-positive/proinsulin-
positive cells suggests that glucagon-positive/GLUT2

cells were unlikely committed to becoming -cells, recall-
ing embryonic development phases when GLUT2 is ex-
pressed temporarily in pancreatic non–-cells, likely
acting as a signal for further development (22).
The histological ﬁndings indicate that damage second-
ary to STZ may be itself a trigger for pancreatic regener-
ative responses; however, it seems unable to sustain
sufﬁcient -cell recovery. To explain the phenomenon
observed in these two monkeys, additional stimuli and
peculiar conditions must be contemplated. One factor of
interest was age: these monkeys were the youngest in the
study (38 and 26 months compared with 49 	 6 months for
all others).
The failure of the graft, i.e., islet -cell dysfunction and
death, may also have fostered regenerating signals, as
described in other forms of pancreatic injury (23). This
would be in line with reports indicating that patients
experiencing islet allograft loss can still exhibit detectable
C-peptide levels and a better management of the diabetic
status (24,25), even if their immunosuppressive regime
included sirolimus and tacrolimus, both known to limit
-cell regeneration (7).
Recovery of the -cell function can occur in nonhuman
primates: the mechanisms that lay behind it, however,
remains to be demonstrated.
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